Ariad Adds Activist Investor Alex Denner of Sarissa to Board
This article is for subscribers only.
Ariad Pharmaceuticals Inc., the cancer-drug maker that lost 58 percent of its value in the last year, added activist investor Alex Denner to its board.
Ariad will also add a second new director to be agreed on with Denner, which would bring the board’s size to 10, the Cambridge, Massachusetts-based company said today in a statement. The stock rose 1.6 percent to $8.87 at the close in New York.